A patient with GOPC–ROS1 fusion–positive pancreatic adenocarcinoma was previously treated with gemcitabine + abraxane + nivolumab followed by repotrectinib (progressed after ∼10 months...After 6 weeks of monotherapy, imaging demonstrated progressive disease in two target lesion liver metastases (+26% overall), together with an increase in the GOPC–ROS1 and CTNNB1 S45F in ctDNA...The patient continued PF-07284892, and lorlatinib was added at 100 mg qd. After 2 weeks of combination (study week 8), both mutations in ctDNA decreased by 95% compared with baseline before starting any study treatment...After 6 weeks of combination (study week 12), target liver lesions decreased by −35% compared with precombination imaging consistent with PR, confirmed after 12 weeks of combination...